Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. ... Hence, anti-IL6 ...
由 GR Burmester 著作 · 被引用 1 次 — Interleukin (IL) 6 is a potent proinflammatory mediator that is important in immune defense and in immune-mediated disease.
由 T Koga 著作 · 2022 · 被引用 9 次 — IL-6 is a potent inducer of serum amyloid A (SAA), which contributes to a positive feedback loop in inflammasomes by acting as a ligand. The ...
由 L Gandini 著作 · 2023 · 被引用 4 次 — In March 2020, tocilizumab, an interleukin (IL)-6 inhibitor, was approved for the treatment of Coronavirus Disease 2019 acute respiratory ...
由 S Hennigan 著作 · 2008 · 被引用 185 次 — Inhibitors of IL-6 were successful in animal models of autoimmune disease paving the way for subsequent studies in humans. The greatest experience to date has ...
2020年9月9日 — The currently approved IL-6 receptor antagonists' tocilizumab and sarilumab can significantly improve in the clinical manifestations of RA.
由 EH Choy 著作 · 2020 · 被引用 450 次 — Pharmacological inhibitors of IL-6 signalling prevent IL-6 from binding to IL-6R by targeting either the cytokine itself or the receptor. b | In ...
2021年7月6日 — Interleukin-6 blocking drugs – tocilizumab and sarilumab – act to suppress this overreaction. The prospective and living network meta-analyses ...